“BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA”. 2016. Mediterranean Journal of Hematology and Infectious Diseases 8 (February): e2016011. https://doi.org/10.4084/mjhid.2016.011.